I think we should've been more critical of the drug being used with Thermodox. That was a variable I frankly didn't consider hard enough. I also agree that going into P2 would've helped to avoid some of the overconfidence. Being fast tracked looked good statistically, but the market cap evaluation was the tell tale sign. That was a clear public record piece of data that helped me avoid more losses.